Search and analyze individual stocks with comprehensive metrics

Innova Captab Limited

INNOVACAPPharmaceuticals & Biotechnology

Fundamental Score

...

Innova Captab Limited Share Price & Market Analysis

Current Market Price (CMP)
829.90
No change data available
Market Cap
4.87K (Cr)
Industry
Pharmaceuticals & Biotechnology

Profitability Metrics

Poor

Return on Equity

14.34%
Poor

Return on Capital Employed

14.63%
Excellent

Operating Profit Margin (5Y)

13.56%
Poor

Dividend Yield

0.00%

Valuation Metrics

Poor

Price to Earnings

37.55x

Market Capitalization

4.87K (Cr)

Industry P/E

33.97x

Growth Metrics

Poor

YoY Quarterly Profit Growth

5.22%
Good

YoY Quarterly Sales Growth

19.46%
Excellent

Sales Growth (5Y)

27.21%
Poor

EPS Growth (5Y)

-37.35%
Excellent

Profit Growth (5Y)

35.71%

Financial Health

Excellent

Debt to Equity

0.35x
Excellent

Interest Coverage

34.99x
Poor

Free Cash Flow (5Y)

-258.21 (Cr)

Ownership Structure

Good

Promoter Holding

50.90%
Poor

FII Holding

0.23%
Good

DII Holding

19.67%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
50.90%
Promoter Holding
4.87K (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of INNOVACAP across key market metrics for learning purposes.

Positive Indicators

6 factors identified

Strong Revenue Growth (19.46%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.

Consistent Growth Track Record (27.21% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.

Strong Profit Growth Track Record (35.71% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.

Strong Interest Coverage (34.99x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.

Balanced Promoter Holding (50.90%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

4 factors identified

Weak Earnings Growth (-37.35% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.

Negative Free Cash Flow (₹-258.21 Cr over 5Y)

Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.

Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.

High P/E Ratio

Observation: Stock may be overvalued relative to earnings.

Analysis: P/E above 30 requires strong growth execution to justify current valuations.

📊 Educational Market Overview

Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.

Loading Peer Comparison

Finding companies in the Pharmaceuticals sector...

Financial Statements

Comprehensive financial data for Innova Captab Limited

About INNOVACAP

Company Details

Symbol:INNOVACAP
Industry:Pharmaceuticals & Biotechnology
Sector:Pharmaceuticals

Market Information

Market Cap:4.87K (Cr)
P/E Ratio:37.55
Beta:N/A

Performance

52W High:N/A
52W Low:N/A
Dividend Yield:0.00%

INNOVACAP Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)14.34%
Return on Capital Employed14.63%
Operating Profit Margin (5Y)13.56%
Debt to Equity Ratio0.35
Interest Coverage Ratio34.99

Growth & Valuation

Sales Growth (5Y)27.21%
Profit Growth (5Y)35.71%
EPS Growth (5Y)-37.35%
YoY Quarterly Profit Growth5.22%
YoY Quarterly Sales Growth19.46%

Frequently Asked Questions

What is the current price of INNOVACAP?

INNOVACAP is currently trading at ₹829.90 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of INNOVACAP shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.

What is the P/E ratio of INNOVACAP and what does it mean?

INNOVACAP has a P/E ratio of 37.55x compared to the industry average of 33.97x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹38 for every ₹1 of annual earnings. This is higher than the industry average, suggesting either growth premium or potential overvaluation.

How is INNOVACAP performing according to Bull Run's analysis?

INNOVACAP has a Bull Run fundamental score of 58.9/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 14.34%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.

What sector and industry does INNOVACAP belong to?

INNOVACAP operates in the Pharmaceuticals & Biotechnology industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Innova Captab Limited. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.

What is Return on Equity (ROE) and why is it important for INNOVACAP?

INNOVACAP has an ROE of 14.34%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Innova Captab Limited generates profits from shareholders' equity. An ROE of 14% means the company generates ₹14 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.

How is INNOVACAP's debt-to-equity ratio and what does it indicate?

INNOVACAP has a debt-to-equity ratio of 0.35, which indicates moderate leverage that should be monitored. This means the company has ₹35 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.

What is INNOVACAP's dividend yield and is it a good dividend stock?

INNOVACAP offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.

How has INNOVACAP grown over the past 5 years?

INNOVACAP has achieved 5-year growth rates of: Sales Growth 27.21%, Profit Growth 35.71%, and EPS Growth -37.35%. This consistent double-digit growth indicates a strong business model and competitive positioning. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.

What is the promoter holding in INNOVACAP and why does it matter?

Promoters hold 50.90% of INNOVACAP shares, with 0.00% of promoter shares pledged. This high promoter holding indicates strong management confidence and alignment with shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.

How does INNOVACAP compare with its industry peers?

INNOVACAP trades at P/E 37.55x vs industry average 33.97x, with ROE of 14.34% and ROCE of 14.63%. The stock trades at a premium to industry average, which may be justified by superior fundamentals. Peer comparison helps identify whether INNOVACAP is outperforming its competitive set in profitability, growth, and valuation metrics.

What is INNOVACAP's market capitalization and what category does it fall into?

INNOVACAP has a market capitalization of ₹4873 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.

What are the key financial ratios to consider for INNOVACAP?

Key ratios for INNOVACAP: ROE 14.34% (Good), ROCE 14.63%, P/E 37.55x, Debt-to-Equity 0.35, Interest Coverage 34.99x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.

How volatile is INNOVACAP stock and what is its beta?

INNOVACAP has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.

What is the 52-week high and low for INNOVACAP?

INNOVACAP has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹829.90, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.

What are the key risks associated with investing in INNOVACAP?

Key risks for INNOVACAP include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.35), and operational challenges. The stock has a Fundamental Score of 58.9/100, indicating moderate risk requiring careful monitoring. Sector-specific risks in Pharmaceuticals & Biotechnology include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.

What is INNOVACAP's operating profit margin and how has it trended?

INNOVACAP has a 5-year average Operating Profit Margin (OPM) of 13.56%, which is good and shows decent operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. Monitor margin trends to assess management's ability to control costs and improve efficiency. Compare with industry peers to understand relative performance.

How is INNOVACAP's quarterly performance in terms of sales and profit growth?

INNOVACAP's recent quarterly performance shows YoY Sales Growth of 19.46% and YoY Profit Growth of 5.22%. This shows decent growth momentum in the business. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.

What is the FII and DII holding pattern in INNOVACAP?

INNOVACAP has FII holding of 0.23% and DII holding of 19.67%, totaling 19.90% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.